De novo lipogenesis products and endogenous lipokines

Diabetes

Volumn 65, Issue 7, 2016, Pages 1800-1807

  Yilmaz, Mustafa ^a   Claiborn, Kathryn C ^a   Hotamisligil, Gökhan S ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FATTY ACID; LIPID; LIPOKINE; PALMITOLEIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; CALORIC RESTRICTION; CONFERENCE PAPER; DIET RESTRICTION; ESTERIFICATION; FATTY ACID SYNTHESIS; FATTY LIVER; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; LIVER; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; FATTY ACIDS; LIPOGENESIS; LIVER; SIGNAL TRANSDUCTION;

EID: 84975893850     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0251     Document Type: Conference Paper

References (81)

1. Schoenheimer R, Rittenberg D. Deuterium as an indicator in the study of intermediary metabolism. Science 1935;82:156-157
2. Shrago E, Glennon JA, Gordon ES. Comparative aspects of lipogenesis in mammalian tissues. Metabolism 1971;20:54-62
3. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118:829-838
4. Shimano H, Shimomura I, Hammer RE, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997;100:2115-2124
5. Knebel B, Haas J, Hartwig S, et al. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS One 2012;7:e31812
6. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;126:12-22
7. Shrago E, Spennetta T. The carbon pathway for lipogenesis in isolated adipocytes from rat, guinea pig, and human adipose tissue. Am J Clin Nutr 1976; 29:540-545
8. Czech MP Cellular basis of insulin insensitivity in large rat adipocytes. J Clin Invest 1976;57:1523-1532
9. Ortega FJ, Mayas D, Moreno-Navarrete JM, et al. The gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. Obesity (Silver Spring) 2010;18:13-20
10. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 2000;97:11371-11376
11. Lan H, Rabaglia ME, Stoehr JP, et al. Gene expression profiles of non-diabetic and diabetic obese mice suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes 2003;52:688-700
12. Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2002;282:E46-E51
13. Kuriyama H, Liang G, Engelking LJ, Horton JD, Goldstein JL, Brown MS. Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. Cell Metab 2005;1:41-51
14. Beaven SW, Matveyenko A, Wroblewski K, et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 2013;18:106-117
15. Carvalho E, Kotani K, Peroni OD, Kahn BB. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am J Physiol Endocrinol Metab 2005;289:E551-E561
16. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993;268:22243-22246
17. Herman MA, Peroni OD, Villoria J, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012;484:333-338
18. Nuotio-Antar AM, Poungvarin N, Li M, et al. FABP4-Cre mediated expression of constitutively active ChREBP protects against obesity, fatty liver, and insulin resistance. Endocrinology 2015;156:4020-4032
19. Bruss MD, Khambatta CF, Ruby MA, Aggarwal I, Hellerstein MK. Calorie restriction increases fatty acid synthesis and whole body fat oxidation rates. Am J Physiol Endocrinol Metab 2010;298:E108-E116
20. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008;134:933-944
21. Dimopoulos N, Watson M, Sakamoto K, Hundal HS. Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J 2006;399:473-481
22. Matsuzaka T, Shimano H, Yahagi N, et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 2007;13: 1193-1202
23. Yang ZH, Miyahara H, Hatanaka A. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay mice with genetic type 2 diabetes. Lipids Health Dis 2011;10:120
24. Guo X, Li H, Xu H, et al. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS One 2012;7:e39286
25. Chan KL, Pillon NJ, Sivaloganathan DM, et al. Palmitoleate reverses high fat-induced proinflammatory macrophage polarization via AMP-activated protein kinase (AMPK). J Biol Chem 2015;290:16979-16988
26. Talbot NA, Wheeler-Jones CP, Cleasby ME. Palmitoleic acid prevents palmitic acid-induced macrophage activation and consequent p38 MAPK-mediated skeletal muscle insulin resistance. Mol Cell Endocrinol 2014;393:129-142
27. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009;15:1383-1391
28. Mozaffarian D, Cao H, King IB, et al. Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. Am J Clin Nutr 2010;92:1350-1358
29. Stefan N, Kantartzis K, Celebi N, et al. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care 2010;33: 405-407
30. Pinnick KE, Neville MJ, Fielding BA, Frayn KN, Karpe F, Hodson L. Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. Diabetes 2012;61:1399-1403
31. Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH; ARIC Study Investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 2003;78:91-98
32. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50:1827-1838
33. Vessby B, Tengblad S, Lithell H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia 1994;37:1044-1050
34. Paillard F, Catheline D, Duff FL, et al. Plasma palmitoleic acid, a product of stearoyl-coA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr Metab Cardiovasc Dis 2008;18:436-440
35. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008;47:348-380
36. Yore MM, Syed I, Moraes-Vieira PM, et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 2014;159:318-332
37. Liu S, Brown JD, Stanya KJ, et al. A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use. Nature 2013;502:550-554
38. Burhans MS, Flowers MT, Harrington KR, et al. Hepatic oleate regulates adipose tissue lipogenesis and fatty acid oxidation. J Lipid Res 2015;56:304-318
39. Chaurasia B, Summers SA. Ceramides - lipotoxic inducers of metabolic disorders. Trends Endocrinol Metab 2015;26:538-550
40. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011;121:4222-4230
41. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996;271: 13018-13022
42. Summers SA, Garza LA, Zhou H, Birnbaum MJ. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 1998;18:5457-5464
43. Hajduch E, Balendran A, Batty IH, et al. Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 2001;44:173-183
44. Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996;271:9895-9897
45. Zhou H, Summers SA, Birnbaum MJ, Pittman RN. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem 1998;273:16568-16575
46. Teruel T, Hernandez R, Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001;50:2563-2571
47. Schilling JD, Machkovech HM, He L, et al. Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J Biol Chem 2013;288:2923-2932
48. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006;55:2579-2587
49. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007;5:167-179
50. Turpin SM, Nicholls HT, Willmes DM, et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014;20:678-686
51. Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59:2453-2464
52. Park TS, Rosebury W, Kindt EK, Kowala MC, Panek RL. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol Res 2008;58:45-51
53. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 2011; 17:55-63
54. Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013;17: 790-797
55. Patel SA, Hoehn KL, Lawrence RT, et al. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology 2012;153:5231-5246
56. Camell CD, Nguyen KY, Jurczak MJ, et al. Macrophage-specific de novo synthesis of ceramide is dispensable for inflammasome-driven inflammation and insulin resistance in obesity. J Biol Chem 2015;290:29402-29413
57. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011;108: 16381-16385
58. Erion DM, Shulman GI. Diacylglycerol-mediated insulin resistance. Nat Med 2010;16:400-402
59. Zechner R, Zimmermann R, Eichmann TO, et al. FAT SIGNALS-lipases and lipolysis in lipid metabolism and signaling. Cell Metab 2012;15:279-291
60. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510:84-91
61. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979;2:433-435
62. Oh DY, Olefsky JM. Omega 3 fatty acids and GPR120. Cell Metab 2012;15: 564-565
63. Calder PC Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 2005;33:423-427
64. Serhan CN Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014;510:92-101
65. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025-1037
66. Kristensen SD, De Caterina R, Schmidt EB, Endres S. Fish oil and ischaemic heart disease. Br Heart J 1993;70:212-214
67. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192: 1197-1204
68. Spite M, Clària J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 2014;19:21-36
69. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010; 142:687-698
70. Ichimura A, Hirasawa A, Poulain-Godefroy O, et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 2012;483: 350-354
71. Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 2011;32:543-550
72. Cani PD, Plovier H, Van Hul M, et al. Endocannabinoids - at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol 2016;12: 133-143
73. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013;17:475-490
74. Massa F, Mancini G, Schmidt H, et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci 2010;30: 6273-6281
75. Bellocchio L, Lafenêtre P, Cannich A, et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 2010;13:281-283
76. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003;74:486-496
77. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005;434: 782-786
78. Schmitz K, Mangels N, Häussler A, Ferreirós N, Fleming I, Tegeder I. Proinflammatory obesity in aged cannabinoid-2 receptor-deficient mice. Int J Obes 2016;40:366-379
79. Riquelme CA, Magida JA, Harrison BC, et al. Fatty acids identified in the Burmese python promote beneficial cardiac growth. Science 2011;334:528-531
80. Stobdan T, Korekar G, Srivastava RB. Nutritional attributes and health application of Seabuckthorn (Hippophae rhamnoides L.)-a review. Curr Nutr Food Sci 2013;9:151-165
81. Small E, Catling PM, Li TSC Blossoming treasures of biodiversity: sea buckthorn (Hippophae rhamnoides)-an ancient crop with modern virtues. Biodiversity 1996;3:25-27